ACP
PRTK

Acuta Capital Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Acuta Capital Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-29,252
Closed -$1.13M – 66
2014
Q4 		$1.13M Buy
+29,252
New +$698K 0.76% 37

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acuta Capital Partners's PRTK Position: Q1 2015 in Review

Acuta Capital Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2015, closing a stake of 29,252 shares — an estimated $1.13M sold.

Acuta Capital Partners first reported a position in PRTK in Q4 2014 and held it in 1 quarter. The position peaked at $1.13M in Q4 2014. 38 funds tracked by Wall St. Rank hold PRTK as of Q1 2015.

  • Acuta Capital Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 29,252 Paratek Pharmaceuticals, Inc. shares in Q1 2015, an estimated $1.13M.
  • Acuta Capital Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Acuta Capital Partners's Paratek Pharmaceuticals, Inc. position peaked at $1.13M in Q4 2014.
  • 38 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.